Figure 1.

Proportion of patients with suboptimal C_trough of lopinavir with respect to lopinavir/ritonavir dose and co-treatment with a non-nucleoside reverse transcriptase inhibitor. The results are expressed as percentages *Significant increase (P < 0.001) in the percentage of patients with C_trough of lopinavir below the threshold value between groups treated with lopinavir/ritonavir 400/100 and a non-nucleoside reverse transcriptase inhibitor and those treated with lopinavir/ritonavir 400/100 alone. LPV Ctrough <3000 ng/ml (▪), LPV Ctrough <1500 ng/ml (□)